<?xml version='1.0' encoding='utf-8'?>
<document id="20211755"><sentence text="The nasty surprise of a complex drug-drug interaction." /><sentence text="In vitro investigation of pharmacokinetic drug-drug interactions (DDIs) has officially been part of the regulatory pathway for new drugs in the USA since the publication of an FDA guidance on the subject in 1997" /><sentence text=" The field has continued to evolve, driven by preclinical and clinical experience, improved understanding of the molecular basis of DDIs, technological advances, and a continuous dialogue between the FDA and pharmaceutical industry scientists" /><sentence text=" Some striking DDIs involve multiple molecular species and targets; their mechanisms and magnitude would have been difficult or impossible to predict with available in vitro tools" /><sentence text=" This article focuses on one such example" /><sentence text="" /></document>